Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)-Reference-Cited by-同舟云学术

Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)

Published:2017-11-16 Issue:6 Volume:177 Page:1552-1561
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Blauvelt A.¹,Ferris L.K.²,Yamauchi P.S.³⁴,Qureshi A.⁵,Leonardi C.L.⁶,Farahi K.⁷,Fakharzadeh S.⁷,Hsu M.-C.⁸,Li S.⁸,Chevrier M.⁸,Smith K.⁹,Goyal K.¹⁰,Chen Y.¹¹,Muñoz-Elías E.J.¹¹,Callis Duffin K.¹²

Affiliation:

1. Oregon Medical Research Center; Portland OR U.S.A.

2. Department of Dermatology; University of Pittsburgh; Pittsburgh PA U.S.A.

3. Dermatology Institute and Skin Care Center; Santa Monica CA U.S.A.

4. Geffen School of Medicine at UCLA; Los Angeles CA U.S.A.

5. Dermatology; Warren Alport Medical School of Brown University; Rhode Island Hospital; Providence RI U.S.A.

6. Dermatology; Saint Louis University School of Medicine; Saint Louis MO U.S.A.

7. Janssen Pharmaceuticals Inc.; Horsham PA U.S.A.

8. Janssen Research & Development LLC; Spring House PA U.S.A.

9. Janssen Research & Development LLC; Titusville NJ U.S.A.

10. Janssen Research & Development LLC; Horsham PA U.S.A.

11. Janssen Research & Development LLC; San Diego CA U.S.A.